Drugs / Aurase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04956900 | Aug 2021 → Feb 2023 | ulcer of lower limbs | SolasCure Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-02-24 | SolasCure Limited | Results SolasCure completes phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel solascure.com ↗
The study demonstrated that its investigational product, Aurase Wound Gel (AWG), heals chronic wounds at a faster rate than current standard of care, providing clinical validation of its ability to deliver continuous enzymatic debridement while simultaneously activating wound healing. |
| 2025-07-08 | SolasCure Limited | Results SolasCure publishes Dose Escalation Study on painless application of Aurase Wound Gel solascure.com ↗
Results show that AWG containing concentrations of tarumase up to 11 U/mL did not result in any increase in patient-reported pain above baseline, either shortly after application or after remaining on the wound for 48–72 hours. |
| 2025-06-16 | SolasCure Limited | Regulatory SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers solascure.com ↗
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational Aurase Wound Gel (AWG), in the treatment of patients with calciphylaxis ulcers. |
| 2024-03-04 | SolasCure Limited | Results SolasCure Publishes Phase IIa Clinical Trial Report in Leading Wound Care Journal solascure.com ↗
The Phase IIa data, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been peer-reviewed and published, providing strong validation as SolasCure progresses into further clinical studies, and marks a significant milestone for the Company. |
| 2023-12-12 | SolasCure Limited | Results SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel solascure.com ↗
SolasCure’s CLEANVLU Phase IIa clinical trial met its primary endpoint; a successful evaluation of safety with no evidence of systemic absorption or adverse systemic effects combined with an excellent local tolerability profile at the wound site. |
| 2023-01-17 | SolasCure Limited | Results SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial solascure.com ↗
The enzyme is shown to have a good safety profile both locally and systemically, providing for a large therapeutic window, which has permitted SolasCure under regulatory review to test the enzyme on real patients with ulcers. |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aurase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04956900 ↗ |
| Modality | Protein / enzyme biologic | “Aurase enzyme” NCT04956900 ↗ |
| Route | Topical | “intended for topical application” NCT04956900 ↗ |